Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

Helsinn Birex Pharmaceuticals wins responsible care award for waste management

Dublin, Ireland (ots)

Helsinn, the Swiss pharmaceutical group,
announced today that its Dublin plant, Helsinn Birex Pharmaceuticals 
(HBP), has been awarded the Irish 2009 Responsible Care® Award for 
Waste Management by PharmaChemical Ireland, the industry association 
representing the Irish chemical and pharmaceutical sector.
"Environmental protection is key to Helsinn and to Helsinn staff",
said Riccardo Braglia, CEO of Helsinn Group. "Since our foundation, 
we have been committed to excellent health, safety and environmental 
management in all our plants worldwide. The Responsible Care Award is
one in a series of acknowledgements we have received in this area so 
far", he concluded. The Helsinn project, which involved the 
application of lean manufacturing concepts, was cited as an excellent
demonstration of waste minimisation and recycling involving strong 
employee engagement. It encompassed two aspects of waste management, 
the reduction of waste at source by developing a solution to recycle 
the waste internally, and a scientific evaluation of a waste stream 
to optimise the safest means of disposal.
Responsible Care® is the chemical industry's global voluntary 
initiative under which companies, through their national 
associations, work together to continuously improve their health, 
safety and environmental performance, and to communicate with 
stakeholders about their products and processes. The Responsible 
Care® ethic helps industry to operate safely, profitably and with due
care for future generations, and was commended by UNEP as making a 
significant contribution to sustainable development at the World 
Summit on Sustainable Development in 2002.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with 
headquarters in Lugano, Switzerland. Helsinn's unique business model 
is focused on the licensing of pharmaceuticals and medical devices in
therapeutic niche areas. The Group in-licenses early stage new 
chemical entities, completes their development from the performance 
of pre-clinical/clinical studies and Chemistry, Manufacturing and 
Control (CMC) development, to the filing for and attainment of their 
market approval worldwide. Helsinn's products are sold directly, 
through the Group subsidiaries, or eventually out-licensed to its 
network of local marketing and commercial partners, selected for 
their deep in-market knowledge and know-how, and assisted and 
supported with a full range of product and scientific management 
services, including commercial, regulatory, financial, legal and 
medical marketing advice. The active pharmaceutical ingredients and 
the finished dosage forms are manufactured at Helsinn's cGMP 
facilities in Switzerland and Ireland, and supplied worldwide to its 
customers.
Helsinn is the worldwide licensor of palonosetron, a second 
generation 5-HT3 receptor antagonist, for the prevention of 
chemotherapy-induced nausea and vomiting (CINV) and of post- 
operative nausea and vomiting (PONV) in patients with cancer, and of 
the original nimesulide, a non-steroidal anti-inflammatory drug 
(NSAID) distributed in more than 50 countries worldwide. Helsinn, 
with a workforce of around 450 employees in Switzerland, Ireland and
USA, reported a 2008 turnover of over CHF 280.3 million (about EUR
178 million), covering 75 countries worldwide, with over 20% of this 
turnover invested in R&D.

Contact:

Helsinn Healthcare SA
Paola Bonvicini Head of Communication & Press Office
Tel: +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA